Genmab | GEN - Betriebsergebnis





Betriebsergebnis Veränderung Datum
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Almirall EUR 30.23M 12.8M 2025-12
Amarin USD -2.26M 564K 2025-12
Amgen USD 3.83B 130M 2026-03
argenx SE USD 394M 22.86M 2026-03
AstraZeneca USD 7.11B 4.14B 2026-03
Bayer EUR 3.53B 2.42B 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Demant DKK 2.09B 224M 2025-12
Exelixis USD 251.34M 15.43M 2026-03
Fresenius Medical Care EUR 268M 395M 2026-03
Genmab DKK 260M 199M 2025-12
GlaxoSmithKline GBP 2.29B 856M 2026-03
GN Store Nord DKK -68M 638M 2026-03
GRIFOLS EUR 249M 26.38M 2026-03
Hikma Pharmaceutical USD 348M 161M 2025-12
Insmed USD -200.28M 49.43M 2026-03
Lakefront Biotherapeutics EUR -63.7M 844.26M 2026-03
Lonza CHF 673M 243M 2025-06
Merck EUR 474M 738M 2025-12
Novartis USD 4.24B 171M 2026-03
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Roche Holding CHF 9.56B 3.8B 2025-12
Sanofi EUR 1.94B 239M 2026-03
UCB EUR 1.29B 571M 2025-12